Arcturus Therapeutics Files 8-K
Ticker: ARCT · Form: 8-K · Filed: Sep 26, 2025 · CIK: 1768224
| Field | Detail |
|---|---|
| Company | Arcturus Therapeutics Holdings Inc. (ARCT) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-disclosure, financial-exhibits
Related Tickers: ARCT
TL;DR
ARCT filed an 8-K, likely containing important updates - check for details.
AI Summary
Arcturus Therapeutics Holdings Inc. filed an 8-K on September 26, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or details about the nature of the disclosure.
Why It Matters
This 8-K filing indicates Arcturus Therapeutics is making a regulatory disclosure and submitting financial exhibits, which could contain important updates for investors.
Risk Assessment
Risk Level: medium — The filing is an 8-K, which often contains material information, but the provided text lacks specific details to assess the immediate impact.
Key Players & Entities
- Arcturus Therapeutics Holdings Inc. (company) — Registrant
- September 26, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 10628 Science Center Drive, Suite 250 (address) — Principal executive offices
- San Diego, California (location) — City and State of principal executive offices
- 92121 (zip_code) — ZIP code of principal executive offices
- (858) 900-2660 (phone_number) — Registrant's telephone number
FAQ
What specific information is being disclosed under Regulation FD?
The provided text of the 8-K filing does not specify the details of the Regulation FD disclosure.
What financial statements and exhibits are being filed?
The filing indicates that Financial Statements and Exhibits are being submitted, but the specific contents are not detailed in the provided text.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is September 26, 2025.
Where are Arcturus Therapeutics Holdings Inc.'s principal executive offices located?
The principal executive offices are located at 10628 Science Center Drive, Suite 250, San Diego, California, 92121.
What is the company's telephone number?
The company's telephone number is (858) 900-2660.
Filing Stats: 905 words · 4 min read · ~3 pages · Grade level 11 · Accepted 2025-09-26 06:01:41
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share ARCT The NASDAQ Stock Mar
Filing Documents
- e664858_8k-arct.htm (8-K) — 28KB
- e664858_ex99-1.htm (EX-99.1) — 7KB
- image1.jpg (GRAPHIC) — 16KB
- image2.jpg (GRAPHIC) — 51KB
- 0001193805-25-001368.txt ( ) — 292KB
- arct-20250926.xsd (EX-101.SCH) — 3KB
- arct-20250926_lab.xml (EX-101.LAB) — 33KB
- arct-20250926_pre.xml (EX-101.PRE) — 22KB
- e664858_8k-arct_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. On September 26, 2025, Meiji Holdings Co., Ltd. announced that its subsidiary, Meiji Seika Pharma Co., Ltd. (" Meiji "), announced today that it launched a new presentation of KOSTAIVE, a self-amplifying mRNA vaccine against COVID-19. The product targets the SARS-CoV-2 Omicron sub lineage JN.1 variant XEC. In non-clinical studies, it induced neutralizing antibodies not only against Omicron JN.1 and XEC, but also against LP.8.1 and the currently circulating variants XFG and NB.1.8.1. The formulation is supplied as a two-dose vial, with one vial per carton. As previously announced on April 11, 2023, Meiji entered into a distribution agreement with Seqirus, Inc. (" CSL Seqirus "), a part of CSL Limited, and one of the world's leading influenza vaccine providers, for the distribution and sales of Arcturus Therapeutics Holdings Inc.'s (the " Company " or " Arcturus ") self-amplifying mRNA vaccine candidate against COVID-19 in Japan. A copy of Meiji's press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information set forth in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchan g e Act "), or otherwise subject to the liabilities of that Section. The information in this Item 7.01 shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in t
Financial Statements and Exhibits
Financial Statements and Exhibits . (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 26, 2025
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arcturus Therapeutics Holdings Inc. Date: September 26, 2025 By: /s/ Joseph E. Payne Name: Joseph E. Payne Title: Chief Executive Officer